Michelle Dawson posts

Post published on Twitter/X on 28 Aug 2013 19:03

Back to posts Previous post Next post
Twitter/X Clinical trial clinicaltrials.gov Extract quoted in the post External link integrated into the post Autism terms
Open original post

Information about the link integrated into the post

Clinical trial

Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (2013). Rapalogues for Autism Phenotype in TSC: A Feasibility Study. ClinicalTrials.gov. Hugo W. Moser Research Institute at Kennedy Krieger, Inc..

More information

Structured cited links

1 cited resource

Clinical trial Fetched Post clinicaltrials.gov

Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (2013). Rapalogues for Autism Phenotype in TSC: A Feasibility Study. ClinicalTrials.gov. Hugo W. Moser Research Institute at Kennedy Krieger, Inc..

Publication date
2013
Identifier
NCT01929642
Authors
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Source
ClinicalTrials.gov
Reference type
clinical_trial
Publisher
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Metadata source
clinicaltrials.gov

Abstract

The purpose of this study is to assess the feasibility and safety of administering rapalogues, sirolimus or everolimus, in participants with Tuberous Sclerosis Complex (TSC) and self-injury and to measure cognitive and behavioral changes, including reduction in autistic symptoms, self-injurious and aggressive behaviors, as well as improvements in cognition across multiple domains of cognitive function.

Open source